Beneficial role of deferasirox and deferiprone in the mobilization of arsenic and recovery of iron in rat tissues

Abstract

The aim of this research was to test the chelation potency of deferasirox (DFS or ICL670)) and deferiprone (L₁) in mobilization of arsenic in arsenic-exposed rats. Male Wistar rats were exposed to 60 mg/kg body weight sodium arsenite in drinking water for six weeks, followed by treatment with DFS (80 mg/kg body weight, oral, once daily), L₁(100 mg/kg body weight, oral, once daily) alone or in combination, for six consecutive days. After chelation therapy, these rats were anesthetized by ether vapor, were immobilized by cervical dislocation and then their heart, liver, kidneys, intestine and blood were sampled for clinical hematological variables and determination of arsenic and iron concentration by Inductively Coupled Plasma/Optical Emission Spectrometry (ICP-OES). Comparison of single and combined therapy showed that the combined chelation therapy (DFS+L₁) is more effective in depleting arsenic concentration from soft tissues. No effects of arsenic or any of the two treatments (L₁ or DFS) on WBC, RBC and Hb were observed. Interestingly, platelet counts showed a decrease in arsenic exposure. The obtained Results of combined treatment should be confirmed by a different experimental model before extrapolation to other systems.

Keywords

Chelation therapy deferasirox deferiprone arsenic toxicity rats

Get full access to this article

View all access options for this article.

References

Galanello

, Agus

, Campus

, Danjou

, Giardina

P.J.

and Grady

R.W.

, Combined iron chelation therapy, Ann N Y Acad Sci 1202 (2010), 79–86.

Piga

, Galanello

, Cappellini

M.D.

, Forni

, Opitz

, Ford

J.M.

, et al, Phase II study of oralchelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics after 6 months of therapy, Blood 100 (2002), 2241–2249.

Kontoghiorghes

G.J.

, Aldouri

M.A.

, Hoffbrand

A.V.

, Barr

, Wonke

, Kourouclaris

and Sheppard

, Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one, Br Med J 295 (1987), 1509–1512.

Flora

S.J.S.

, Bhattacharyan

and Vijayaraghavan

, Combined therapeutic potential of meso dimercaptosuccinic acid and calcium edentate on the mobilization and distribution of lead in experimental lead intoxication in rats, Fundam Appl Toxicol 25 (1995), 233–240.

Mourad

F.H.

, Hoffbrand

A.V.

, Sheikh-Taha

, Koussa

, Khoriaty

A.L.

and Taher

, Comparison between desferrioxamine and combined therapy with desferrioxamine and deferriprone in iron overloaded thalassaemia patients, Br J Haematol 121 (2003), 187–189.

Amiri

, Fatemi

S.J.

and Fatemi

S.N.

, Removal of thallium by combining desferrioxamine and deferiprone chelators in rats, Biometals 20 (2007), 159–163.

Fatemi

S.J.

, Tubafard

and Nadi

, Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity, Med Chem Res 18 (2009), 179–186.

Voskaridou

, Christoulas

and Terpos

, Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting sever iron overload after single-agent chelation therapies, Br J Haematol 154 (2011), 654–656.

Hershko

, Konijn

A.M.

, Nick

H.P.

, Breuer

, Cabatchik

Z.I.

and Link

, ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in ironloaded rat heart cell in culture, Blood 97 (2001), 1115–1122.

10.

Piga

, Gaglioti

, Fogliacco

and Tricta

, Comparative effects of deferiprone and deferoxamine onsurvival and cardiac disease in patients with thalassemia major: A retrospective analysis, Haematologica 88 (2003), 489–496.

11.

, Zhou

, Kong

and Hider

R.C.

, Chelating agents for the treatment of systemic iron overload, Curr Med Chem 19 (2012), 2816–2827.

12.

Westwood

, Anderson

L.J.

and Pennell

D.J.

, Treatment of cardiac iron overload in thalassemia major, Haematologica 88 (2003), 481–482.

13.

Steinhauser

, Heinz

, Bartholoma

, Weyhermuller

, Nick

and Hegetschweiler

, Complex formation of ICL670 and related ligands with Fe(III) and Fe(II), Eur J Inorg Chem 21 (2004), 4177–4192.

14.

Evans

R.W.

, Kong

and Hider

R.C.

, Iron mobilization from transferrin by therapeutic iron chelating Agents, Biochim Biophys Acta 1820 (2012), 282–290.

15.

Neufeld

E.J.

, Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions, Blood 107 (2006), 3436–3441.